search
Back to results

Assessment of Performance and Safety of an Asymmetric Balloon in the Treatment of Intranasal Bleeding Managed in an Emergency Setting (BATSI)

Primary Purpose

Epistaxis

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
asymmetric balloon
Sponsored by
Dianosic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Epistaxis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age > or = 18 years
  • Male and female
  • bleeding uncontrolled with digital compression
  • Patient registered at social security
  • Patient who gave informed consent

Exclusion Criteria:

  • Allergy to xylocaine
  • Impossibility to give patient information (severe massive epistaxis, difficulty to understand, non awaken patient…)
  • Patient in custody of court
  • Patient under guardianship or curator

Sites / Locations

  • CHU Strasbourg

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

asymmetric balloon

Arm Description

Asymmetric air filled (max 25 cc, Leur lock syringe) epistaxis balloon

Outcomes

Primary Outcome Measures

Device performance
Absence of bleeding following balloon inflation during first 48 hours and absence of rebreeding following removal at 48 hours and 9 days following removal
Device safety
Pain score on a VAS (Visual Analogic Scale)

Secondary Outcome Measures

QoL
RhinoQoL (Rhino Quality of Life) score

Full Information

First Posted
April 8, 2019
Last Updated
August 30, 2019
Sponsor
Dianosic
search

1. Study Identification

Unique Protocol Identification Number
NCT03912051
Brief Title
Assessment of Performance and Safety of an Asymmetric Balloon in the Treatment of Intranasal Bleeding Managed in an Emergency Setting
Acronym
BATSI
Official Title
Assessment of Performance and Safety of an Asymmetric Balloon in the Treatment of Intranasal Bleeding Managed in an Emergency Setting
Study Type
Interventional

2. Study Status

Record Verification Date
August 2019
Overall Recruitment Status
Completed
Study Start Date
March 27, 2019 (Actual)
Primary Completion Date
June 30, 2019 (Actual)
Study Completion Date
July 18, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dianosic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Between 10 and 12% of the general population suffers from epistaxis, out of which 10% would need to be medically managed. Most of patients treated for epistaxis are managed through emergency departments. The involvement of the ENT (ear, nose and throat) surgeon might be required in more complex situations in order to control bleeding. Usually, nasal packing packing is used as a first line option after failure of digital compression. Epistaxis balloons are often used after failure of nasal packing Balloons are effective in approximately 60% of the patients with a rapid control of bleeding by compression followed by an absence of rebreeding after balloon removal. The main challenges for patients treated with this device are i) pain upon balloon introduction and inflation ii) discomfort upon introduction in the nasal cavity as well as during balloon maintenance during 24 to 72 hours of tamponade iii) blood retention between distal and proximal balloons that favors infection iv) limited breathing capabilities through the nostrils which increases general discomfort v) negative aesthetic impact for the patient vi) septal and alar necrosis risk in case of prolonged compression. Moreover, epistaxis leading to an hospitalization between 24 to 48h are not rare (>11 000 in France in 2017 according to ATIH). Those hospitalizations are often decided in order to ensure an optimal patient monitoring following packing or epistaxis balloon placement. In order to address those adverse events while keeping the same efficacy and avoiding hospitalizations or reducing their duration, the use of an asymmetric, more physiological, easy to use and mainly intranasal (discreet proximal extremity) is studied.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Epistaxis

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
asymmetric balloon
Arm Type
Experimental
Arm Description
Asymmetric air filled (max 25 cc, Leur lock syringe) epistaxis balloon
Intervention Type
Device
Intervention Name(s)
asymmetric balloon
Other Intervention Name(s)
epistaxis balloon
Intervention Description
Asymmetric balloon for treatment of intranasal bleeding
Primary Outcome Measure Information:
Title
Device performance
Description
Absence of bleeding following balloon inflation during first 48 hours and absence of rebreeding following removal at 48 hours and 9 days following removal
Time Frame
12 days
Title
Device safety
Description
Pain score on a VAS (Visual Analogic Scale)
Time Frame
12 days
Secondary Outcome Measure Information:
Title
QoL
Description
RhinoQoL (Rhino Quality of Life) score
Time Frame
12 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age > or = 18 years Male and female bleeding uncontrolled with digital compression Patient registered at social security Patient who gave informed consent Exclusion Criteria: Allergy to xylocaine Impossibility to give patient information (severe massive epistaxis, difficulty to understand, non awaken patient…) Patient in custody of court Patient under guardianship or curator
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christian Debry, Pr
Organizational Affiliation
CHU Strasbourg (Univ Hosp Strasbourg)
Official's Role
Principal Investigator
Facility Information:
Facility Name
CHU Strasbourg
City
Strasbourg
State/Province
Grand Est
ZIP/Postal Code
67000
Country
France

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Assessment of Performance and Safety of an Asymmetric Balloon in the Treatment of Intranasal Bleeding Managed in an Emergency Setting

We'll reach out to this number within 24 hrs